Hodgkin S Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hodgkin s disease. 48 active patents protecting 4 drugs from 2+ originators. First major cliff: 2032. Daily refresh.

4
Approved drugs
48
Active US patents
59/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Hodgkin S Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 33 patents Baxter 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hodgkin s disease. Each bar = one year. Y-axis scaled to peak year (9 patents).

5
27
2
28
2
30
5
32
4
33
7
34
9
35
7
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
11904046 Cortef method of use 75 2043-02-23
12133914 Cortef method of use 75 2043-02-23
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
10022502 Decadron method of use 45 2034-06-22

Related